Chirdeep Patel, MD
Interventional Cardiology · Allentown, PANPI 1164658050
Payments from drug & device makers
Across 662 payments — averaging $73.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$12K
- Boston Scientific$9K
- Shockwave Medical, Inc$7K
- Abiomed$5K
- Medtronic$4K
- Philips North America LLC$3K
- plus $9K from 33 others
What the payments were for
- Consulting fees$10,66822%
- Speaking & faculty fees$4,4259%
- Grants$2000%
- Travel & lodging$11,49624%
- Food & beverage$22,05545%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 16 | $11,746 |
| Boston Scientific | 238 | $8,746 |
| Shockwave Medical, Inc | 37 | $6,935 |
| Abiomed | 141 | $4,752 |
| Medtronic(2 entities) | 54 | $4,334 |
| Philips North America LLC | 17 | $3,095 |
| Abbott | 53 | $3,016 |
| Penumbra, Inc. | 2 | $1,283 |
| Edwards Lifesciences | 9 | $1,206 |
| W. L. Gore & Associates, Inc. | 17 | $507 |
| Cardiovascular Systems Inc. | 16 | $456 |
| Inari Medical, Inc. | 6 | $394 |
| Teleflex LLC | 3 | $265 |
| Johnson & Johnson | 5 | $211 |
| Cathworks, Inc. | 3 | $195 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $180 |
| AstraZeneca | 2 | $155 |
| Asahi Intecc USA, Inc. | 2 | $150 |
| Livanova USA, Inc. | 2 | $129 |
| Esperion Therapeutics, Inc. | 1 | $115 |
| Novartis | 6 | $106 |
| Bard Peripheral Vascular, Inc. | 1 | $95 |
| Surmodics, Inc. | 1 | $94 |
| Actelion Pharmaceuticals US, Inc. | 1 | $92 |
| Terumo Medical Corporation | 1 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Saranas, Inc. | 1 | $56 |
| Amgen | 3 | $56 |
| Siemens Medical Solutions USA, Inc. | 1 | $53 |
| Biotronik Inc. | 1 | $49 |
| Lundbeck LLC | 2 | $41 |
| Novo Nordisk | 1 | $35 |
| Cardiva Medical, Inc. | 1 | $30 |
| Preventice Services, LLC | 1 | $27 |
| Cordis US CORP. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$6,221
- COREVALVE EVOLUT R$2,667
- (9525) Intracardiac Und$1,950
- Impella$1,946
- Indigo$1,283
- AMPLATZER Occluders$960
- Azurion 7 M20$710
- Optis Coronary Imaging System$568
- SYNERGY$407
- WATCHMAN FLX$381
- FLOWTRIEVER CATHETER, S$334
- CT THROMBECTOMY SYSTEM KIT$334
- SYMPLICITY G3$282
- Diamondback Coronary$274
- AVVIGO Guidance System$273
- ONYX FRONTIER$273
- COMET$266
- CoreValve Evolut$249
- (9520) IGT Devices Undivided$208
- FFRangio$156
How this compares
$48,844 in reported general payments places this provider in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $85,348 |
| EntrestoSacubitril/Valsartan | 20 | $32,538 |
| Repatha SureclickEvolocumab | 26 | $22,997 |
| XareltoRivaroxaban | 14 | $21,490 |
| BrilintaTicagrelor | 14 | $14,911 |
| Atorvastatin Calcium | 167 | $2,375 |
| Metoprolol Succinate | 122 | $2,343 |
| Rosuvastatin Calcium | 117 | $1,907 |
| Ranolazine ErRanolazine | 17 | $1,793 |
| ClopidogrelClopidogrel Bisulfate | 89 | $1,772 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 53 | $1,217 |
| Ezetimibe | 32 | $900 |
| Amlodipine Besylate | 71 | $781 |
| Nitroglycerin | 27 | $717 |
| Carvedilol | 71 | $713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $85,34867 claims |
| NovartisEntresto | $106 | $32,53820 claims |
| Johnson & JohnsonXarelto | $211 | $21,49014 claims |
| AstraZenecaBrilinta | $155 | $14,91114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Allentown
- Nainesh PatelAllentown$1.1M
- Shailendra SinghAllentown$906K
- William GrayWynnewood$3.3M
- Eric GnallWynnewood$2.4M
- Howard HerrmannPhiladelphia$2.2M
- Ramzi KhalilPittsburgh$1.6M
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1.3M
- David LasordaPittsburgh$1.1M
- Jay GiriPhiladelphia$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.